ABSTRACT
Rationale & Objective: This study investigated the effects on patients' outcomes of using medium cutoff (MCO) versus high-flux (HF) dialysis membranes. Study Design: A retrospective, observational, multicenter, cohort study. Setting & Participants: Patients aged greater than 18 years receiving hemodialysis at the Baxter Renal Care Services dialysis network in Colombia. The inception of the cohort occurred from September 1, 2017, to November 30, 2017, with follow-up to November 30, 2019. Exposure: The patients were divided into 2 cohorts according to the dialyzer used at the inception: (1) MCO membrane or (2) HF membrane. Outcomes: Primary outcomes were the hospitalization rate from any cause and hospitalization days per patient-year. Secondary outcomes were acute cardiovascular events and mortality rates from any cause and secondary to cardiovascular causes. Laboratory parameters were assessed throughout the 2-year follow-up period. Analytical Approach: Descriptive statistics were used to report population characteristics. Inverse probability of treatment weighting was applied to each group before analysis. All categorical variables were compared using Pearson's χ2 test, and continuous variables were analyzed with the t test. Baseline differences between groups with a value of >10% were considered clinically meaningful. Laboratory variables were measured at 5 consecutive time points. A between-patient effect was analyzed using a split-plot factorial analysis of variance. Results: The analysis included 1,098 patients, of whom 564 (51.3%) were dialyzed with MCO membranes and 534 (48.7%) with HF membranes. Patients receiving hemodialysis with MCO membranes had a lower all-cause hospitalization incidence rate (IR) per patient-year (IR = 0.93; 95% CI, 0.82-1.03) than those receiving hemodialysis with HF membranes (IR = 1.13; 95% CI, 0.96-1.30), corresponding to a significant incident rate ratio (MCO/HF) of 0.82 (95% CI, 0.68-0.99; P = 0.04). The frequency of nonfatal cardiovascular events showed statistical significance, with a lower incidence in the MCO group (incident rate ratio = 0.66; 95% CI, 0.46-0.96; P = 0.03). No statistically significant differences in all-cause time until death were observed (P = 0.48). Albumin levels were similar between the 2 dialyzer cohorts. Limitations: Despite the robust statistical analysis, there remains the possibility that unmeasured variables may still generate residual imbalance and, therefore, skew the results. Conclusions: The incidences of hospitalization and cardiovascular events in patients receiving hemodialysis were lower when dialyzed with MCO membranes than HF membranes. A randomized controlled trial would be desirable to confirm these results. Trial Registration: Clinical Trials.gov, ISRCTN12403265.
ABSTRACT
La infección por el virus de la inmunodeficiencia adquirida (VIH) ha aumentado su prevalencia a nivel mundial, la tercera parte de los pacientes desarrollan compromiso de la función renal y pueden llegar a requerir terapia de reemplazo renal. La terapia antirretroviral altamente efectiva (HAART) ha mejorado la supervivencia de los pacientes con dicha infección y ha motivado que esta población sea hoy considerada para ingresar a lista de trasplantes. Presentamos el caso de un paciente con enfermedad renal crónica secundaria a toxicidad por indinavir, quien permaneció durante cuatro años en hemodiálisis y recibe injerto renal de donante vivo, ha tenido seguimiento durante siete años con evolución favorable, sin rechazo, infecciones oportunistas ni complicaciones cardiovasculares, en manejo con terapia HAART logrando óptimo control virológico e inmunológico. La infección por VIH no es una contraindicación para recibir un trasplante renal y contribuye a mejorar calidad de vida y morbimortalidad en esta población. (Acta Med Colomb 2015; 40: 162-165).
Infection by human immunodeficiency virus (HIV) has increased its prevalence worldwide. One third of patients develop renal function involvement and might require renal replacement therapy. The highly active antiretroviral therapy (HAART) has improved survival of patients with this infection and this has motivated that this population be now considered for entering a transplant list. We report the case of a patient with chronic kidney disease secondary to toxicity by indinavir, who spent four years in hemodialysis and receives renal graft from living donor, has been followed up for 7 years with favorable evolution, without rejection, opportunistic infections or cardiovascular complications, and is being managed with HAART achieving optimal virological and immunological control. HIV infection is not a contraindication for renal transplantation and contributes to improving quality of life, morbidity and mortality in this population. (Acta Med Colomb 2015; 40: 162-165).
